Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Biologicals ; 41(6): 435-8, 2013 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-24064050

RESUMEN

The potencies of therapeutic preparations of gonadotrophins of human, urinary origin, which comprise a heterogenous mix of isoforms with follicle-stimulating hormone (FSH) and luteinizing hormone (LH) bioactivities, are standardized by WHO International Standards (IS). We report here, the evaluation, through an international collaborative study, of a candidate preparation, coded 10/286, to replace the 4th IS, 98/704, for human, urinary FSH and LH (Menotrophin) which has been used for many years for the potency assignment of therapeutic preparations using bioassays. The mean FSH and LH bioactivities of 10/286, determined by in vivo bioassays in terms of 98/704, were 183 IU per ampoule (95% confidence limits 165-202) and 177 IU per ampoule (95% confidence limits 159-197), respectively.


Asunto(s)
Hormona Folículo Estimulante/normas , Hormona Luteinizante/normas , Menotropinas/normas , Bioensayo/métodos , Bioensayo/normas , Femenino , Fármacos para la Fertilidad Femenina/normas , Fármacos para la Fertilidad Femenina/uso terapéutico , Fármacos para la Fertilidad Femenina/orina , Hormona Folículo Estimulante/uso terapéutico , Hormona Folículo Estimulante/orina , Humanos , Cooperación Internacional , Hormona Luteinizante/uso terapéutico , Hormona Luteinizante/orina , Menotropinas/uso terapéutico , Menotropinas/orina , Estándares de Referencia , Organización Mundial de la Salud
2.
Fertil Steril ; 106(7): 1714-1717.e1, 2016 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-27678033

RESUMEN

OBJECTIVE: To determine whether the addition of either urinary or recombinant LH in patients undergoing routine clinical care improved the outcome in terms of the number of oocytes recovered for insemination or the delivery rate per initiated cycle. DESIGN: Cohort analysis. PATIENT(S): Couples undergoing IVF/ICSI in 158 institutions in 15 countries in Latin America. SETTING: In vitro fertilization clinics. INTERVENTION(S): We compared the outcome of three different protocols of COH, including rFSH only, rFSH plus rLH, and rFSH plus hMG. MAIN OUTCOME MEASURE(S): The number of mature oocytes recovered and inseminated; proportion of ETs at the blastocyst stage; clinical pregnancy, miscarriage, and delivery rates; proportion of cycles with embryo cryopreservation; and mean number of embryos cryopreserved. RESULT(S): After correcting for the age of the female partner, body mass index, number of embryos transferred, and stage of embryo development at transfer, we found that LH addition was not associated with an increase in the mean number of metaphase II oocytes inseminated or with an increase in the delivery rate or changes in the miscarriage rate. CONCLUSION(S): Our study strongly suggests that in routine clinical practice, the type of controlled ovarian stimulation-FSH alone or in combination with LH-has little impact on the outcome of assisted reproductive technology; therefore a more friendly and accessible alternative should be favored.


Asunto(s)
Fármacos para la Fertilidad Femenina/uso terapéutico , Fertilización In Vitro , Hormona Folículo Estimulante Humana/uso terapéutico , Infertilidad/terapia , Hormona Luteinizante/uso terapéutico , Inducción de la Ovulación/métodos , Adulto , Criopreservación , Quimioterapia Combinada , Femenino , Fertilidad , Fármacos para la Fertilidad Femenina/efectos adversos , Fármacos para la Fertilidad Femenina/orina , Hormona Folículo Estimulante Humana/efectos adversos , Humanos , Infertilidad/diagnóstico , Infertilidad/fisiopatología , América Latina , Nacimiento Vivo , Hormona Luteinizante/efectos adversos , Hormona Luteinizante/orina , Masculino , Recuperación del Oocito , Inducción de la Ovulación/efectos adversos , Embarazo , Índice de Embarazo , Proteínas Recombinantes/efectos adversos , Proteínas Recombinantes/uso terapéutico , Sistema de Registros , Inyecciones de Esperma Intracitoplasmáticas , Resultado del Tratamiento
3.
Rapid Commun Mass Spectrom ; 16(8): 761-7, 2002.
Artículo en Inglés | MEDLINE | ID: mdl-11921260

RESUMEN

Using gas chromatography/electron impact-mass spectrometry (GC/EI-MS) and high performance liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry (HPLC/APCI-MS/MS), the structures of cyclofenil metabolites in human urine have been assigned. The hydroxyl metabolites liberated from the glucuronide conjugates after acid hydrolysis were characterized as the trimethylsilyl (O-TMS) derivatives using GC/MS. The conjugate glucuronide forms were detected without hydrolysis by HPLC/MS. Cyclofenil was not observed in urine. Tentative structures for the two metabolites are proposed.


Asunto(s)
Ciclofenil/orina , Fármacos para la Fertilidad Femenina/orina , Adulto , Biotransformación , Cromatografía Líquida de Alta Presión , Femenino , Cromatografía de Gases y Espectrometría de Masas , Humanos , Masculino
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA